The Coherex FlatStent™: An advance in patent foramen ovale closure

Expert Review of Medical Devices

Volumn 7, Issue 2, 2010, Pages 193-199

  Ruygrok, Peter N ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Closure; Cryptogenic stroke; Paradoxical embolism; Patent foramen ovale

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; NITINOL; POLYURETHAN;

ANTICOAGULANT THERAPY; CARDIOVASCULAR EQUIPMENT; CLINICAL STUDY; COMPOSITE MATERIAL; DEVICE THERAPY; DISEASE ASSOCIATION; EQUIPMENT DESIGN; FLUOROSCOPY; GOOD LABORATORY PRACTICE; HEART VENTRICLE SEPTUM; HUMAN; IMPLANTATION; MIGRAINE; NONHUMAN; PATENT FORAMEN OVALE; PATENT FORAMEN OVALE CLOSURE DEVICE; PATIENT SAFETY; REVIEW; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT RESPONSE; ARTICLE; BLOOD VESSEL PROSTHESIS; EQUIPMENT; STENT;

BLOOD VESSEL PROSTHESIS; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FORAMEN OVALE, PATENT; HUMANS; STENTS;

EID: 77949343526     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.72     Document Type: Review

References (24)

1. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the frst 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin. Proc. 59, 17-20 (1984).
2. Fisher DC, Fisher EA, Budd JH, Rosen SE, Goldman ME. The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study. Chest 107, 1504-1509 (1995).
3. Schneider B, Zienkiewicz T, Jansen V, Hofmann T, Noltenius H, Meinertz T. Diagnosis of patent foramen ovale by transesophageal echocardiography and correlation with autopsy fndings. Am. J. Cardiol. 7 7, 1202-1209 (1996).
4. Kerut EK, Norfeet W T, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J. Am. Coll. Cardiol. 38, 613-623 (2001).
5. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. Am. Heart. J. 130, 1083-1088 (1995).
6. Schwerzmann M, Nedeltchev K, Lagger F et al. Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology 65, 1415-1418 (2005).
7. Reisman M, Christofferson RD, Jesurum J et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J. Am. Coll. Cardiol. 45, 493-495 (2005).
8. Chen GP, Goldberg SL, Gill EA Jr. Patient foramen ovale and the platypnea-orthodeoxia syndrome. Cardiol. Clin. 23, 85-89 (2005).
9. Germonpre P, Hastir F, Dendale P, Marroni A, Nguyen AF, Balestra C. Evidence for increasing patency of the foramen ovale in divers. Am. J. Cardiol. 95, 912-915 (2005).
10. Overall JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 55, 1172-1179 (2000).
11. Mas JL, Arquizan C, Lamy C et al.; for the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N. Engl. J. Med. 345, 1740-1746 (2001).
12. Hanna JP, Sun JP, Furlan AJ, Stewart WJ, Sila CA, Tan M. Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. Stroke 25, 782-786 (1994).
13. O'Gara PT, Messe SR, Tuzcu EM, Catha G, Ring JC. Percutaneous device closure of patent foramen ovale for secondary stroke prevention. J. Am. Coll. Cardiol. 53, 2014-2018 (2009).
14. Scherzmann M, Windecker S, Wahl A et al. Percutaneous closure of patent foramen ovale: impact of device on safety and efficacy. Heart 90, 186-190 (2004).
15. Mullen MJ, Hildick-Smith D, De Giovanni JV et al. BioSTAR Evaluation Study (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial level shunts. Circulation 114, 1962-1967 (2006).
16. Windecker S, Wahl A, Chatterjee T et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long term risk of recurrent thromboembolic events. Circulation 101, 893-898 (2000).
17. Sievert H, Ruygrok P, Salkeld M et al. Transcatheter closure of patent foramen ovale with radiofrequency: acute and intermediate term results in the frst 144 patients. Cathet. Cardiovasc. Intervent. 73(3), 368-373 (2009).
18. Billinger K, Ostermayer SH, Carminati M et al. HELEX Septal Occluder for transcatheter closure of patent foramen ovale: multicentre experience. EuroIntervention 1, 465-471 (2006).
19. Braun MU, Fassbender D, Schoen SP et al. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J. Am. Coll. Cardiol. 39, 2019-2025 (2002).
20. Anzola GP, Morandi E, Casilli F, Onorato E
21. Jones R, Sievert H, Ruygrok P, Grube E, Schofer J. The Coherex FlatStent: closure inside the patent foramen ovale. EuroIntervention 5(Suppl. E) (2009).
22. Ruygrok P, Sievert H, Schoefer J et al. Safety and efficacy of the Coherex Flatstent patent foramen ovale closure device. Am. J. Cardiol. 104, 29D (2009).
23. Beelke M, Angeli S, Del Sette M et al. Prevalence of patent foramen ovale in subjects with obstructive sleep apnea: a transcranial Doppler ultrasound study. Sleep Med. 4, 219-223 (2003).
24. Johanssen MC, Eriksson P, Peker Y, Hedner J, Rastam L, Lendblad U. The infuence of patent foramen ovale on oxygen desaturation in obstructive sleep apnoea. Eur. Respir. J. 29, 149-155 (2007).